Carolyn M. Boudreau, Ph.D.

Carolyn has extensive scientific expertise across academic and industry environments. She contributed to patent development and prosecution as a research scientist, including serving as a liaison between research teams and legal counsel to assess prior art, design patent portfolios, and evaluate freedom-to-operate (FTO) matters. Carolyn’s scientific work has supported the advancement of nasal spray therapeutics, antibody engineering, vaccine design, and nanobody discovery, with specific applications in pandemic preparedness and mucosal immunity.

Prior to entering the legal field, Carolyn led scientific programs in multiple startup environments. She independently developed a novel in vivo nanobody discovery platform, integrating cutting-edge wet lab techniques with artificial intelligence (AI)-driven bioinformatics. Working with an international team of scientists, business development professionals, and legal experts at a biotechnology company based in the Netherlands, she developed a drug discovery pipeline for nasal spray therapeutics to prevent infection with respiratory viruses. Her leadership in these environments extended to personnel management, operational oversight, regulatory compliance, and client engagement, including proposal development and project execution.

Carolyn’s doctoral research focused on functional humoral immune responses to influenza vaccinations, utilizing systems immunology approaches, in vitro and in vivo models, and machine learning (ML). She collaborated with industry partners on vaccine development and supervised junior researchers. Her work has been recognized with multiple publications in high-impact journals, including Nature Communications, Cell Reports Medicine, and Scientific Reports, and she has presented her findings at international conferences and symposia.